A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers

V-7404, a direct-acting enterovirus (EV) 3C protease inhibitor, is being developed as a treatment option for serious EV infections, including infections in immunodeficient people excreting vaccine-derived polioviruses. V-7404 may be combined with pocapavir (V-073), a capsid inhibitor, to treat these...

Descripción completa

Detalles Bibliográficos
Autores principales: Kankam, Martin K., Burns, Jennifer M., Collett, Marc S., Corrado, Michael L., Hincks, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448163/
https://www.ncbi.nlm.nih.gov/pubmed/34370575
http://dx.doi.org/10.1128/AAC.01029-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448163/
https://www.ncbi.nlm.nih.gov/pubmed/34370575
http://dx.doi.org/10.1128/AAC.01029-21

Ejemplares similares